Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune disease of multi-system organ involvement, characterized by autoantibody production and tissue injury. SLE primarily affects women of childbearing age (F:M ratio 9:1) and has a prevalence rate of ෂ1 case/2500. 1 Among African-American populations, SLE is three times more prevalent than in European-Americans, manifests at a younger age, and is more severe than in other American populations. [2] [3] [4] . Though the etiology of SLE is still unknown, genetic and environmental factors are involved. A genetic component is supported by familial clustering with s estimates between 10 and 20, as well as higher concordance rates between monozygotic twins (Ͼ20%) relative to dizygotic twins and other full siblings (2-5%). [5] [6] [7] [8] Numerous candidate gene loci (including multiple alleles from the HLA region, Fc␥ receptors, and complement components) have been implicated through case-control association studies. [9] [10] [11] [12] [13] [14] [15] [16] [17] In addition, multiple susceptibility loci have been detected in inbred mouse strains. [18] [19] [20] [21] [22] [23] [24] [25] [26] With the development of detailed physical and genetic maps, mapping disease genes by genetic linkage is now a standard approach for studying complex diseases. However, establishing linkage remains an imposing challenge. Not only must one labor with an unknown mode of inheritance and the possible involvement of multiple genes and environmental factors when studying a complex disease, but genome scan results have a propensity to vary between studies. These variations are often attributed to genetic heterogeneity of sample populations collected, the employment of different analysis methods, and variable systematic error that may be present in the data.
In 1995, Lander and Kruglyak suggested that in order to maintain the probability of encountering a false positive linkage signal below 5% when executing a genome scan, a threshold of LOD у 3.3 (or the rough equivalent, P р 0.00005) must be obtained before an effect is considered significant. 27 Likewise, they suggested an effect should only be considered suggestive of linkage once it has surpassed a threshold of LOD у 1.9 (P р 0.0017). 27 These thresholds were estimated for extended pedigrees and depended upon the collection ascertainment. For studies consisting of only affected sibling pairs, these thresholds were raised to LOD у 3.6 and 2.2 respectively. To date, there are seven published genome scans and two candidate region linkage studies performed on SLE patients. [28] [29] [30] [31] [32] [33] [34] [35] [36] These studies have identified seven loci that meet the threshold for significance, and Ͼ50 loci that meet the threshold for suggestive linkage.
Association studies
Association studies are used to localize genetic effects and identify differences in the distribution of allele frequencies according to phenotypic status within populations. These types of studies can provide important insights into the mechanisms of complex diseases. Finding association, however, does not indicate the allele identified is the polymorphism responsible for the genetic effect. Before the polymorphism is accepted as a disease allele, there should be no other polymorphism with a greater association effect within the region, and the role of the polymorphism needs to be understood in disease pathogenesis. For example, HLA-B2705 and ankylosing spondylitis are associated in every population in which this association has been evaluated. 37 It would therefore be a surprise if this was not the gene. The biological role of HLA-B2705, however, still remains unknown three decades later. The frequency of Fc␥RIIA alleles with lupus is an example of an association that is found by some groups but not others. This may be explained by ethnic variation, locus heterogeneity, admixture, artifact, or linkage disequilibrium.
Some HLA alleles may be associated with a decreased risk of SLE. This particular phenomenon has been observed with HLA-B40 among an Australian population. 55 Likewise, the presence of DR4 in a Japanese population has been reported as a decreased risk factor of SLE. 56 It is obvious that associations with the HLA alleles are consistently observed among lupus patients, thereby supporting a lupus susceptibility gene in this region on chromosome 6. However, this region is complex due to the relatively large genomic distances that are in linkage disequilibrium, as well as the multiple alleles at multiple loci that appear to be associated with lupus. Efforts to establish which of these loci are responsible for the observed effects are underway.
Complement components
The complement system is involved in both innate and adaptive immunity and is essential for host defense. It consists of at least 20 serum proteins and glycoproteins that interact sequentially to facilitate antigen clearance and the generation of an inflammatory response. It also promotes defense by way of utilizing the membrane attack complex to lyse microbial agents. Several components within the complement system are members of the major histocompatibility complex class III region. C4A, C4B and C2, are early players in the classical complement activation pathway and have been identified as risk factors in SLE.
Complete and partial deficiencies of the C4 loci, either C4A or C4B, are risk factors for the development of SLE. Patients with complete C4 deficiency (four null alleles) have been found to manifest an early age of SLE onset, renal disease, and anti-Ro without anti-DNA autoantibodies. 15 Complete C4 deficiency, however, is rare; partial C4 deficiency is more commonly observed. The C4A null allele (C4A*Q0) is associated with almost every SLE population studied to date. 9, 15, [57] [58] [59] Petri et al 60 observed a significant increase in the C4A null allele among SLE patients versus controls in both African-American (61% vs 13%, P Ͻ 0.001) and European-American (43% vs 25%, P Ͻ 0.01) populations. A significant increase of the C4B null allele (C4B*Q0) in lupus patients has been demonstrated in a Spanish SLE population (OR: 6.0). 61 The C4A null allele is in linkage disequilibrium with HLA-DR3. 62 However, C4A allelic associations with SLE have been noted in some populations without observing an association with HLA-DR3, thereby providing evidence that C4 may have an effect that is independent of HLA. 60, 61, [63] [64] [65] The most frequent homozygous complement deficiency in humans is that of C2.
66 C2 deficiency, however, only affects approximately 0.01% of the general population. 67, 68 In lupus patients, the prevalence of C2 deficiency is significantly higher, 0.4-2%. 67, 69 Thirty-three percent of individuals of European descent who have C2 deficiency develop lupus. 70 C2 deficient lupus patients are more inclined to have cutaneous and articular involvement, but mild or absent pleuropericardial, neurologic or renal involvement. 71 Some C2 deficient patients tend to be susceptible to photosensitivity, produce antiRo autoantibodies and are prone to serious and recurrent infections. 71, 72 To date, individuals deficient in C1q carry the highest risk of SLE identified. Of those individuals who are C1q deficient, more than 92% are affected with SLE. 73 Both complete and partial C1q deficiencies have been reported among SLE patients. 14, 70, 73 For those patients, the disease is severe and some die from meningitis or recurrent infection. 74 It has been suggested that because C1q deficiency leads to severe lupus phenotypes and an excessive prevalence of disease, it is vital in the host's defense against immune-complex-mediated disease. 74 Ultimately, deficiencies in these particular complement components may lead to impaired opsonization or transport of immune complexes. In turn, this may result in decreased clearance of immune complexes with subsequent inflammation and tissue damage. 10 These variants code for arginine (R131) and histidine (H131) at position 131, and vary in their binding of IgG2. Indeed, Fc␥RIIA-H131 is the only Fc receptor that effectively binds human IgG2. 75 It was therefore conceptually consistent with current thinking when patients homozygous for the R131 allele were shown to exhibit decreased binding of IgG2 and an increased risk of susceptibility to SLE.
Fc␥ receptors
The relationship between the Fc␥RIIA-H/R131 polymorphism and lupus susceptibility, however, has been controversial. Among African-American SLE populations, Salmon et al 12 77 distinguished a skewing of the Fc␥RIIA-R/R131 genotype among their European patients when compared to controls (30% vs 21%, respectively, OR: 1.6, P = 0.07). Other studies, however, did not find an association within their respective European populations. [78] [79] [80] These differences may be attributable to genetic variances among different ethnic groups. Fc␥RIIA does appear to play an important role in some SLE populations, while playing a smaller (maybe even undetectable) role in others. Some have suggested that these studies may be variably detecting some other locus that is in linkage disequilibrium with Fc␥RIIA rather than the Fc␥RIIA locus itself. Nonetheless, ethnic variation, admixture and artifact may each have some contribution in the associations found in some SLE populations but not others.
A polymorphism within the Fc␥RIIIA gene (F/V176) has been associated with SLE susceptibility. 13 Fc␥RIIIA receptors aid in cell death and are found on the surface of natural killer cells, mononuclear phagocytes and renal mesangial cells. 81 The single base pair T to G substitution at nucleotide 559 results in a substitution of phenylalanine (F) with valine (V) at amino acid position 176 within the extracellular domain 2, the domain that is crucial for ligand binding. Like Fc␥RIIA, the different alleles vary in their ability to bind to IgG. Fc␥RIIIA-V176/V176 homozygotes have a higher binding affinity for IgG, while 77 The third critical Fc␥ receptor that appears to play a role in the immunopathogenesis of SLE is Fc␥RIIIB. This gene is selectively expressed on neutrophils and has a low-affinity for binding to IgG. The Fc␥RIIIB polymorphism (Fc␥RIIIB-NA1/NA2) is codominantly expressed as neutrophil antigen 1 (NA1) and 2 (NA2). 83, 84 These two alleles differ in amino acid sequence and two glycosylation sites. 83, [85] [86] [87] Individuals who exhibit the Fc␥RIIIB-NA2/NA2 genotype have a decreased capacity to mediate phagocytosis than individuals with the Fc␥RIIIB-NA1/NA1 genotype. 88 Two studies have identified patients who express a rare NA-null allele, leading to a complete absence of the Fc␥RIIIB gene itself. 89, 90 Because these null alleles are extremely rare in the general population, the null allele itself my represent a risk factor for the development of lupus. A study performed to assess the possible association between Fc␥RIIIB and SLE was evaluated in a Japanese collection of SLE patients. A significant difference in the frequency of the Fc␥RIIIB-NA2/NA2 genotype was observed among SLE patients versus controls (23.5% vs 11.5%, respectively, OR: 2.52, 95% CI: 1.33-4.79, P = 0.008). 91 In addition, there was an under-representation of the NA1 allele (OR: 4.0, 95% CI: 0.21-0.75, P = 0.005) and an over-representation of the NA2 allele among patients with SLE (OR: 1.86, 95% CI: 1.07-3.21, P = 0.027).
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Other genes Associations between SLE and the genes previously mentioned are not entirely sufficient to explain the susceptibility observed. Weak associations have been identified with other genes, but additional studies are needed to further implicate these genes as susceptibility loci for SLE. These include interleukin-10, the FAS and FASL genes, and mannose-binding lectin (MBL). Some evidence has been obtained for possible association with SLE and alleles at Bcl-2, CTLA4, the T cell receptors, prolactin, tumor necrosis factor (TNF) and TNF receptors. [92] [93] [94] [95] [96] [97] [98] Even in aggregate, however, these effects are too small to explain the genetics of SLE. Therefore, other genes still remain to be identified.
Interleukin-10:
Interleukin-10 (IL-10) is mapped to the long arm of chromosome one (1q31-32) and participates in programmed cell death. It blocks antigen presentation to T-cells and decreases the production of a number of cytokines synthesized by activated macrophages and helper T-cells (interferon-gamma, interleukins 2 and 3, and tumor necrosis factor). IL-10 also stimulates B cells in vitro, resulting in hyperactivated proliferation and differentiation. 99 Among SLE patients, the numbers of IL-10-producing cells are increased in the peripheral blood, resulting in these patients having an abundance of pathogenic autoantibodies. [100] [101] [102] Moreover, lupus-prone mice that are administered recombinant IL-10 develop accelerated autoimmune disease. 103 For these reasons, IL-10 is a possible candidate gene in lupus susceptibility.
Through efforts to map the IL-10 gene, Eskdale et al 104 identified two polymorphic dinucleotide repeats in the promoter region of the gene (IL10.G and IL10.R located 1.1 kb and 4.0 kb upstream of the transcription start site, respectively). They assessed the possible implication of these two microsatellites among a group of 56 Caucasian SLE patients and 102 matched controls and observed an allelic skewing at the IL10.G microsatellite among the SLE patients. 105 When evaluating the IL10.G microsatellite within an Italian SLE sample population, the IL10.G 140 base pair allele was found to be significantly increased in the SLE patients versus controls (RR: 1.78, 95% CI: 1.19-2.66). 106 To date, no study has observed an association between the IL10.R microsatellite and SLE. 
FAS and FAS ligand:
The FAS and FAS ligand genes are members of the TNF and TNF receptor gene families and, together, are important in cytotoxic T-cell mediated apoptosis.
9 FAS was implicated in lupus when the lpr/lpr phenotype of the MRL mouse was explained by a frameshift mutation and premature stop codon in the fas gene. 107, 108 These mice develop lymphoproliferation and an SLE-like autoimmune disease.
The possible association between FAS and SLE has been studied in a Japanese collection of 82 SLE patients and 132 controls. 108 A novel polymorphism was identified at nucleotide 297, which was found to be in linkage disequilibrium with the FAS polymorphism at nucleotide 416. The 297C/416G genotype frequency was significantly increased among SLE patients compared to controls (12.2% vs 1.5%, respectively) with a relative risk of 5.0. 109 More recently, the FAS promoter −670 polymorphism was evaluated among a sample of 87 Korean SLE patients. 110 No significant difference was found in the genotypic distributions between patients and controls. However, when possible associations with clinical manifestations were assessed, a significant difference was observed among the genotypic frequencies of patients with anti-nRNP antibodies compared to SLE patients without anti-nRNP antibodies ( 2 = 13.29, P = 0.001). A second cohort was examined, which later replicated the association found among the first group of patients. 110 Several studies have evaluated the possible association between SLE and a structural mutation in the FASL gene. 111 113 This protein plays two crucial roles in host protection against pathogens: (1) MBL-targets are phagocytosed after direct interaction between the target and the MBL receptors (one of which is the C1qR P receptor, a C1q/MBL/surfactant protein A receptor the mediates enhanced phagocytosis 114 ), and (2) through triggering its MBL-associated serine proteases (MASP-1 and MASP-2), MBL is capable of activating the classical complement pathway. [114] [115] [116] Three single nucleotide polymorphisms are located in the structural region of the gene at codons 52, 54 and 57, and two are in the promoter region at −550H/L and −221X/Y. [117] [118] [119] [120] The three polymorphisms located in the structural region result in amino acid changes and are associated with reduced serum levels of MBL. 118 Patients who are homozygous for the variant alleles are at risk of immunodeficiency. 121 Dysfunctional MBL variants have been studied in several SLE populations. A mutation at codon 54 in exon 1 of the MBL gene was analyzed in a Spanish population of 50 SLE patients and 49 matched controls. 122 This polymorphism affects the stability of the protein itself as well as its ability to activate complement. Davies et al found this mutation in 52% of their SLE patients and 31% of the controls (OR: 2.4, 95% CI: 1.1-5.6). 122 They also observed that in 41% of their patients, the dysfunctional MBL allele and the C4 null allele were both present, while being present in only 16% of the controls (OR: 3.2, 95% CI: 1.2-8.1). 122 The codon Asp 54 and Glu 57 mutations in MBL have also been evaluated in an African-American SLE population, with the gene frequencies of both mutations being significantly higher in the SLE patients compared to the controls (0.163 vs 0.087, P = 0.02; 0.125 vs 0.047, P = 0.007). 123 The −550 and −221 promoter polymorphisms were also evaluated, and a higher frequency of these polymorphisms in the SLE patients was observed as well (P = 0.04 and P = 0.03, respectively). Overall, the prevalence of any mutation in the SLE population was 46% versus 23% in the controls (P = 0.001), and the SLE relative risk for a person with at least one disease-associated mutation was 2.0 .
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The two promoter mutations were evaluated among a Chinese SLE sample population. The gene frequencies of all four alleles were higher in the SLE patients compared to controls (H/L: P = 0.018; Y/X: P = 0.019). 124 Those SLE patients who displayed significantly increased frequencies of the promoter genotypes expressed 60-70% lower MBL levels than healthy controls. The H/Y and L/X haplotypes resulted in the highest (2099 g/L) and lowest (940 g/L) MBL levels, respectively, both in the Chinese SLE patients and healthy controls.
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Lupus susceptibility loci mapped using murine lupus models Studies using murine lupus models have greatly advanced the understanding of the genetics of SLE. Murine linkage studies identify loci that contribute to the pathogenesis of murine SLE and, in turn, establish syntenic regions along the human genome that can then be studied in man. Three inbred mouse models are commonly used to study lupus: (1) the New Zealand F 1 hybrid model (NZB × NZW)F 1 , (2) the lpr/lpr MRL model and (3) the BXSB model. All three models develop a severe lupus-like nephritis.
(NZB × NZW)F1
The New Zealand hybrid model is by far the most extensively studied murine model of spontaneously arising (Table 4) . d Indicates region that contains a suggestive human linkage signal (Table 5) .
Genes and Immunity lupus nephritis. 125 Besides the various MHC susceptibility loci that have been identified, more than 15 non-MHC susceptibility loci have been found using this model. Drake et al 18 identified the first murine lupus susceptibility locus (Nba1, or New Zealand Black autoimmunity) on chromosome 4 using (NZB × NZW)F 1 × NZW backcross mice in 1994. Since then, they have also identified two additional New Zealand Black autoimmunity loci, Nba2 and Nba3, on chromosomes 1 and 7, respectively. 19, 26 More recently, this group identified the interferon-inducible gene, Ifi202, as being the gene responsible for the Nba2 contribution. 126 Other groups have mapped susceptibility loci to various murine chromosomes using New Zealand hybrid mice [22] [23] [24] (Table 1 ). Kono et al 22 identified eight lupus susceptibility loci (Lbw-8) in the (NZB × NZW)F 2 intercross mice ( Table 1) . Associations were established between certain loci and early mortality, glomerulonephritis, and antichromatin antibody production. One locus, Lbw2, appeared to play a critical role in survival. All early mortality mice shared a particular Lbw2 allele, thereby suggesting this allele may be involved in the development of early-onset disease. One locus was linked to all three traits, while others were linked to just two traits or only one. Kono et al 22 suggest that the underlying genetic makeup of lupus is due to distinct, but additive, genetic contributions.
Another group consisting of Edward Wakeland, Laurence Morel and Chandra Mohan, among others, has concentrated on an NZB and NZW hybrid (NZM/Aeg2410) strain. They have investigated possible epistatic interactions in lupus and have identified four lupus glomerulonephritis susceptibility loci mapped to murine chromosomes 1, 4, 7 and 17 (named Sle1, 2, 3 and H-2 respectively) ( Table 1) . Sle1 was found to trigger the loss of tolerance to nuclear antigens, while Sle2 resulted in B cell hyperactivity and Sle3 impacted T-cell activation and apoptosis. [127] [128] [129] Fine mapping revealed that Sle11 was composed of four closely linked genes (Sle1a-Sle1d). 130 To evaluate the role of genetic interactions, Wakeland's group has developed bi-congenic strains that carried the susceptibility alleles in various combinations and observed an epistatic interaction of Sle1 and Sle3. 131 Together, they mediate the development of fatal lupus on a B6 background but not on the background of the parental NZW strain. They hypothesized the NZW genome was somehow suppressing the severe autoimmune phenotypes and subsequently identified four SLE suppressor loci (Sles1-4) whose combined effect explained the lack of fatal disease in the NZW strain 131 (Table 1) . A three-component model of lupus pathogenesis was then proposed: first, the loss of immune tolerance to nuclear autoantigens by Sle1 and c1q resulted in autoimmunity; second, genes such as Sle2, Sle3, lpr, gld or Yaa hyperactivated or dysregulated immune components; and third, genes such as Sle6 resulted in final organ damage. If Sles1, 2, and 3 suppressed Sle1, 2 and 3, respectively, then disease progression did not occur. 132 More recently, Morel et al 130 evaluated bi and tricongenic strains. In doing so, Sle1 was identified as being the key mediator involved in the development of fatal lupus. When combined with Sle2, Sle3 or Yaa, the resulting phenotype was the development of systemic autoimmunity with kidney failure caused by severe glomerulonephritis. However, when two combinations were made between Sle2, Sle3 or Yaa, fatal disease was not the result. It was therefore concluded that Sle1, through its mediation of loss of tolerance to chromatin, was essential for disease. Sle1 would therefore be an attractive target for therapeutic intervention in SLE. It should be noted that the Sle1 susceptibility locus with its four individual genes is positioned on the murine genome in a region that is syntenic to 1q on the human genome containing the Fc receptors mentioned above.
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MRL
The MRL background is an admixture of the LG/J, AKR/J and C3H/Di strains and is predisposed to autoimmunity. When the lpr (or fas) or the gld (or fasl) are bred into an MRL background, a much more rapid and severe form of lupus nephritis occurs. 125, 134 The first genome scan performed on MRL-Fas lpr × Mus castaneus × MRL-Fas lpr backcross mice identified two suggestive MRL susceptibility loci (Lrdm1 and Lrdm2) mapped to murine chromosomes 7 and 12, as well as the lpr mutation to murine chromosome 19. 135 Vidal et al 25 later attempted a genome scan using the (MRL-Fas lpr × B6-Fas lpr )F 2 intercrossed strain to examine the phenotype of splenomegaly and lymphadenopathy using markers that covered a greater percentage of the genome than Watson et al. 135 They were able to identify four loci, Lmb1-Lmb4, mapped to murine chromosomes 4, 5, 7, and 10, respectively (see Table 1 ).
BXSB
The BXSB model is a recombinant inbred of the C57BL/6J and SB/Le strains. 136 This strain carries a single yaa gene mutation that accelerates a more rapid and severe lupuslike disease in male animals. 137 Hogarth et al, 21 the first to perform a genome scan on the BXSB model, identified three previously unknown susceptibility loci on chromosome 1 (Bxs1-3) . The interval defined by Bxs3 (renamed Yaa4) was mapped just proximal to the previously identified region containing SLE susceptibility loci Lbw7, Nba2 and Sle1, and was syntenic to 1q41-43 in the human genome, a region of substantial interest in the study of human SLE. 35, 138 More recently, the same group identified two additional susceptibility loci, Bxs4 (renamed Sle10) and −5 (renamed Sle11), on chromosomes 1 and 3, respectively. 20 The list of known genetic linkages to murine lupus or its intermediate phenotype is quite lengthy ( Table 1) . Studies to confirm these findings and identify specific genes responsible for these effects are underway.
Human genetic linkage studies
The premise of genetic linkage analysis is the detection of alleles at a particular marker locus that segregate with the disease of interest through a family. Linkage is a function of physical distance along DNA. The closer the marker and disease loci are, the more likely they are to be linked, thus tending to travel together from parent to offspring. As the distance between loci increases, they are less likely to travel together due to an increasing probability of recombination events. Once the probability reaches 0.50, two loci essentially segregate randomly and are not considered linked. Conversely, as the distance between the marker and disease gene decreases, the probability of a recombination occurring approaches zero. Genetic linkage analysis, therefore, identifies two loci that are in sufficient physical proximity such that the probability of recombination during meiosis is less than 50%. Dense marker maps spanning the human genome are now available due to recent technological advances in human molecular genetics, as well as the continued drive to finish mapping the human genome. The hunt for disease genes, therefore, is carried out through linkage analysis using the Ͼ10 000 microsatellite markers (http://www.marshfieldclinic.org/genetics/) and the Ͼ1200 000 single nucleotide polymorphisms (http://snp.cshl.org/) now available.
Seven published genome scans and two candidate gene studies have been carried out on SLE subjects with each group using a different ascertainment sampling strategy (Table 2) . [28] [29] [30] [31] [32] [33] [34] [35] [36] This choice of sampling scheme is related to the choice of analytical method used to reveal linkage or genetic association (Table 3) . At the same time, the methods chosen are somewhat dependent upon what is known regarding the etiology of lupus.
Lupus is believed to be an oligogenic trait. It is, therefore, likely that the population carries susceptibility controlled by several genes, simultaneously. Likewise, multiple analytical methods may be required, and the results from all of the methods, including both the differences and similarities between them, are needed to gain an understanding of the genetic linkages and associations involved in lupus.
In turn, the power of each analysis method chosen is S77 (1) influenced by the particular sample collection. Collecting affected sibling pairs has been a popular choice. The affected sibling pair method examines how often two affected siblings share the same parental allele. When linkage is present, these siblings share a higher proportion of alleles identical by descent than the normal proportions of 1:2:1 (for 0, 1 and 2 alleles, respectively). Many sibling-pair analysis methods are now available for Genes and Immunity evaluating affected sibling-pairs as well as analyzing affected-unaffected discordant sibling pairs. A great benefit of the analysis methods developed for these types of collections is that no assumptions are made concerning the mode of inheritance of the trait studied. This is particularly advantageous in complex diseases where the mode of inheritance is usually not known. A disadvantage of the affected sibling pair collections, however, is the potential deficiency in the quality control of the genotype data. Identification of Mendelian inconsistencies, an important element of quality control, may be problematic in nuclear pedigrees, particularly if parental data are unavailable or cannot be easily inferred through the collection of additional family members.
Collections of extended pedigrees have their own advantages. Almost all of the linkage analysis methods can be applied to the data. It has also been suggested that distant affected relative pairs have more crossovers than affected sibling pairs and, hence, have greater power to reveal linkage. However, for the maximum-likelihood model-based (LOD score) analysis methods, the mode of inheritance must be specified. For complex diseases, this can be a disadvantage, again, since the mode of inheritance is often not known. In attempts to bypass this, some groups use a screening set of several different modes of inheritance and differing amounts of penetrance when performing the analyses.
One of the first human linkage studies in rheumatic autoimmune diseases was performed in 1986 by Bias et al. 28 They evaluated 18 pedigrees affected with various autoimmune diseases (including SLE) for linkage to an autoimmune trait defined by an autoantibody profile. Using a limited number of markers, they were unable to detect any significant linkage effects, but did conclude, nonetheless, that there is an autoimmune phenotype segregating as a Mendelian autosomal dominant trait.
More recently, Tsao et al 35 evaluated a region on chromosome 1 (1q31-q42) because of evidence for linkage previously found within an alleged syntenic region in a murine model (Table 1) . Five markers located within a 15 cM region at 1q41-q42 showed suggestive evidence for linkage, with the greatest evidence for linkage at D1s229 (P = 0.0005). Further evaluation by Tsao et al 35 narrowed the region to 5 cM when they obtained a LOD score of 3.3 between D1s2860 and D1s213 using multipoint analysis. They reported an association with a candidate gene, PARP (poly (ADP-ribose) polymerase). 139 Other investigators, however, have not found an association between SLE and PARP in their collections. 140, 141 Linkage to D1s2616, a marker mapped within this 5 cM region, has been observed in two studies with convincing evidence to support a SLE susceptibility gene being responsible for the linkages to this region (LOD = 1.15 and P = 0.004, respectively, Figure 1) 142 (unpublished data). Seven genome scans have been performed using various populations and analytical approaches. [29] [30] [31] [32] [33] [34] 36 Of the multiple candidate susceptibility loci that have been identified, seven surpass the suggested significance threshold of LOD у3.3 (Table 4 ). In addition to these seven established linkage effects, multiple candidate susceptibility loci have also been identified (Table 5 ), but chromosomal locations implicated vary, most likely a result of genetic heterogeneity or in the analysis method used (Tables 2 and 3) .
Linkage to Fc␥RIIA (1q22-23) was first identified in a genome scan performed on 94 pedigrees collected in Oklahoma (LOD = 3.45) ( Table 5) . 33 With the addition of 32 pedigrees since the original genome scan, the evidence for linkage to Fc␥RIIA increased to a LOD = 4.03 (Table  4) . The study population was enriched for African-American pedigrees relative to the other collections, and the main effect at Fc␥RIIA originated from those pedigrees. No other study has been able to confirm this linkage; however, none of the other study populations are enriched with African-American pedigrees ( Table 2 ). This effect is supported, however, by Shai et al 34 who identified a suggestive effect with D1s484 (LOD = 1.51), 3 cM distal to Fc␥RIIA. Linkage to D1s484 has also been supported by Tsao et al 143 (P = 0.019). In addition, GrayMcGuire et al, 31 though using many of the same pedigrees as Moser et al, 33 applied a different analysis method evaluating linkage in affected relative pairs (ARP, a subtest of SAGE 4.0, Beta version 3). 31 Two suggestive linkages were identified in the region that contains Fc␥RIIA: D1s1679 with LOD = 2.11 at 2 cM proximal to Fc␥RIIA, and D1s1677 with LOD = 2.41 at 3 cM proximal to Fc␥RIIA. 31 The case-control association studies in human lupus and linkage studies in murine models of SLE (both discussed previously) powerfully corroborate the observed linkage effect at Fc␥RIIA.
The linkage identified by Lindqvist et al 32 at D2s125 (SLEB2) is convincing (LOD = 4.24) ( Table 4 ). Since the original genome scan, they have analyzed an additional 15 markers in this region using an extended set of Icelandic, Swedish and Norwegian pedigrees containing 76 affecteds. 144 They observed a multipoint LOD = 6.03 between D2s125 and D2s2985, making this the highest LOD score reported to date. No other study has reported a linkage to this region, though one study identified an effect to a region just centromeric to 2q37 using principal component analysis and an alternately defined phenotype. 145 Gray-McGuire et al 31 used the revised multipoint Haseman-Elston regression technique for sibling pairs Indicates unpublished OMRF effect has decreased since the Moser et al genome scan (1998). 33 Bold lettering corresponds to a result suggestive of linkage (LOD Ͼ 1.9 or P Ͻ 0.01). Italic fields correspond to an effect found using different methods with the same pedigree collection. Underlined fields correspond to effects found in different collections at the same locus. Brackets after loci correspond to effect found in different collections at loci within 5 cM (and which were not tested at the same locus). Brackets after the P value column satisfy the empiric criteria for suggestive or established linkage by effects at two neighboring loci (Goldin et al, 1999) 146 as follows: 1 Established at an average P р 0.00305 for 10 cM, 2 Suggestive at an average P р 0.02314 for 10 cM, 3 Established at an average P р 0.00120 for 5 cM, 4 Suggestive at an average P р 0.01275 for 5 cM, 5 Established at an average P р 0.00083 for 3 cM, 6 Suggestive at an average P р 0.00775 for 3 cM.
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(SIBPAL2) and a conditional logistic regression technique for affected relative pairs (ARP). They observed linkage to 4p16-15 with D4s2366 using both techniques (P = 0.0007 and LOD = 3.62, respectively) ( Tables 4 and 5) . When using traditional maximum-likelihood modelbased methods, this effect at D4s2366 was also seen using the same data set (LOD = 1.86), as well as suggestive evidence to D4s403, 13 cM centromeric to D4s2366 (LOD = 1.84) ( Table 5) .
To confirm the established linkage to D4s2366 (LOD = 3.62), genotypic data were obtained from the Minnesota collections for D4s2366, D4s403 and D4s2639, spanning 21 cM. Using ARP, a LOD = 1.5 was obtained in the 4p16-15 region with the European American affected relative pairs. This effect reaches the suggested criterion for confirmation by Lander and Kruglyak of P = 0.01 (or its equivalent of LOD = 1.18). 27 The murine SLE gene, Sle6, is syntenic to this region, providing corroborating evidence to support a SLE susceptibility gene being mapped to the 4p16-15 region.
Linkage to D4s1627 (LOD = 3.20) was identified by Lindqvist et al, 32 in which they presented the effect as mapped to the 4p16-15 region. However, the public databases now place this marker at 4p13 (50 cM centromeric to D4s2366), so this effect does not add additional confirmation to the linkage detected at 4p16-15.
As mentioned above, numerous murine as well as human associations have been found between SLE and the HLA region on the short arm of chromosome 6, and as a result, an effect here is expected. Several studies have identified linkages to loci both within and around the HLA region. The Minnesota collection has their greatest effect here with LOD = 4.16 at D6s426 (Table 4) . 29, 30 The Oklahoma pedigrees have since confirmed this effect (P = 0.0007) (unpublished data, Table 5 ). Finally, there is a modest effect in the Swedish families at TNF␣, also in this region (LOD = 1.9). 32 The sixth significant SLE susceptibility linkage is mapped to 16q13 and was identified by Gaffney et al. 29, 30 They obtained a LOD = 3.85 at D16s415 (Table 4) . No other study shows linkage to this region. Though this effect has not yet been confirmed, it is a region of interest since several other autoimmune diseases (IDDM, multiple sclerosis and Crohn's disease) map to this region as well.
The seventh and most recently identified SLE susceptibility locus was found as a result of Nath et al 36 stratifying their pedigree collection by clinical manifestations in hopes of creating a more homogeneous set of pedigrees. Sixteen European-American pedigrees were selected from their total 160 pedigree selection based on the presence of any SLE affected expressing vitiligo. Genetic linkage using this phenotype was identified at 17p13 between D17s974 and D17s1298 (Z lr = 4.01, P = 2.8 × 10 −5 , LOD = 3.64).
This method, conditioning the analysis on pedigrees based on clinical manifestations, is becoming a focus of much recent work. Sophisticated computers with faster processing speeds, large collections of pedigrees and sophisticated databases containing clinical information are allowing groups to ask questions of their data, not previously thought possible. Through the use of principal components and the utilization of clinical data, Rao et al 145 collapsed the 11 ACR criteria for SLE into seven SLE related traits (dermatological, renal, immunological, hemGenes and Immunity atological, neurological, cardiopulmonary and arthritic manifestations) and performed a genome scan. Linkage was observed at D7s1818 with the dermatologic trait. Further analysis showed that malar rash was the component most responsible for this linkage (P = 0.0046). 145 These studies suggest that clinical and environmental features of SLE patients are likely to have important implication for SLE genetics. Indeed, associated clinical and laboratory features of SLE have their own potential to be explained by genetic variation between individuals. The clinical, laboratory and environmental features of SLE appear to have great potential to reveal the genetics of SLE, whether applied to stratifying pedigrees or applied as the conditioning variable in multiple regression strategies.
In addition to the significant linkages described above, 53 linkages have been identified as meeting or surpassing the threshold of being suggestive of linkage (LOD у1.9, P Ͻ 0.01) using SLE as the phenotype (Table 5) . Certainly, further studies are needed in order to distinguish false positives from true linkages. Nonetheless, the genomic regions that at present appear to have the strongest linkages overall, and should therefore be the primary focus of fine mapping efforts and candidate gene studies, are found on chromosomes 1, 2, 4, 6, 16 and 17.
Conclusion
Through the efforts of both association and genetic linkage studies, it is obvious that multiple susceptibility loci contribute to the immunopathogenesis of SLE. In addition to several loci with significant evidence for linkage, seven published genome scans have identified 53 loci that may play at least a partial role in the genetic composition of SLE. Given the modest magnitude of the many genetic efforts present and the problems this often poses for the replication of linkage results in complex diseases, the studies reported to date describing the complex genetics of lupus are very encouraging. Convincing evidence for multiple linkages along with confirmation of several genetic effects has been clearly illustrated in human SLE. Although identification of the disease genes responsible for these linkages, as well as for the multitude of suggestive linkages remains a formidable challenge, this is an exciting time for unraveling the genetic complexities of SLE.
